Double trouble: combined large-cell neuroendocrine and small-cell lung carcinoma.
作者信息
Fisch David, Christopoulos Petros
机构信息
Department of Medical Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.
Translational Lung Research Center at Heidelberg University Hospital, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
出版信息
Transl Cancer Res. 2022 Sep;11(9):3006-3011. doi: 10.21037/tcr-22-1984.
Abstract
摘要
相似文献
1
Double trouble: combined large-cell neuroendocrine and small-cell lung carcinoma.双重麻烦：大细胞神经内分泌癌与小细胞肺癌合并存在
Transl Cancer Res. 2022 Sep;11(9):3006-3011. doi: 10.21037/tcr-22-1984.
2
Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.手术切除的单纯型和混合型肺大细胞神经内分泌癌的不同特征和生存差异。
Ann Surg Oncol. 2022 Sep;29(9):5666-5678. doi: 10.1245/s10434-022-11610-4. Epub 2022 May 11.
3
[Large-cell neuroendocrine carcinoma of the lung - challenges of diagnosis and treatment].[肺大细胞神经内分泌癌——诊断与治疗的挑战]
Orv Hetil. 2020 Feb;161(8):313-319. doi: 10.1556/650.2020.31581.
4
A case of synchronous double primary lung cancer with neuroendocrine features.一例具有神经内分泌特征的同步双原发性肺癌病例。
Jpn J Clin Oncol. 1999 Apr;29(4):219-25. doi: 10.1093/jjco/29.4.219.
5
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.纯型和混合型肺大细胞神经内分泌癌患者临床结局的差异：一项多中心回顾性研究。
Lung Cancer. 2020 Jan;139:118-123. doi: 10.1016/j.lungcan.2019.11.004. Epub 2019 Nov 11.
6
Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer.大细胞神经内分泌癌：一种侵袭性非小细胞肺癌。
J Thorac Cardiovasc Surg. 2005 Jul;130(1):166-72. doi: 10.1016/j.jtcvs.2005.02.064.
7
Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.原发性肺神经内分泌肿瘤中雌激素和孕激素受体的免疫组化表达
Arch Pathol Lab Med. 2008 Dec;132(12):1889-95. doi: 10.5858/132.12.1889.
8
Diagnostic criteria and evolving molecular characterisation of pulmonary neuroendocrine carcinomas.肺神经内分泌癌的诊断标准及不断演变的分子特征
Histopathology. 2022 Nov;81(5):556-568. doi: 10.1111/his.14714. Epub 2022 Aug 2.
9
Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases.肺大细胞神经内分泌癌：87例临床病理研究
J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92. doi: 10.1067/mtc.2002.122523.
10
Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.合并肺小细胞癌、大细胞神经内分泌癌及腺癌的遗传学研究
Virchows Arch. 2008 Jul;453(1):107-15. doi: 10.1007/s00428-008-0620-y. Epub 2008 Jun 13.
引用本文的文献
1
Combined large‑cell neuroendocrine carcinoma and small‑cell lung cancer: A case report.合并大细胞神经内分泌癌和小细胞肺癌：一例报告。
Oncol Lett. 2024 Aug 8;28(4):484. doi: 10.3892/ol.2024.14618. eCollection 2024 Oct.
2
Transformation of -positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report.阿来替尼耐药后阳性非小细胞肺癌转化为小细胞肺癌并对阿特珠单抗联合治疗有反应：一例报告
Transl Lung Cancer Res. 2023 Mar 31;12(3):637-646. doi: 10.21037/tlcr-23-154. Epub 2023 Mar 28.
本文引用的文献
1
Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report.肺原发性进行性神经内分泌肿瘤伴转移部位联合分类：一例报告
Transl Cancer Res. 2022 Jul;11(7):2438-2442. doi: 10.21037/tcr-21-2793.
2
Genomic Feature of a Rare Case of Mix Small-Cell and Large-Cell Neuroendocrine Lung Carcinoma: A Case Report.罕见混合型小细胞与大细胞神经内分泌肺癌的基因组特征：一例报告
Front Oncol. 2022 Jan 18;11:794744. doi: 10.3389/fonc.2021.794744. eCollection 2021.
3
Metastatic -Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel.转移性突变肺神经内分泌肿瘤对奥拉帕尼和紫杉醇表现出显著反应。
JCO Precis Oncol. 2021 Nov;5:751-755. doi: 10.1200/PO.20.00400.
4
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma.转移性大细胞神经内分泌肺癌患者治疗模式与结局的综合剖析
Front Oncol. 2021 Jul 8;11:673901. doi: 10.3389/fonc.2021.673901. eCollection 2021.
5
Immunotherapy in small cell lung cancer: one step at a time: a narrative review.小细胞肺癌的免疫治疗：循序渐进：一篇叙述性综述
Transl Lung Cancer Res. 2021 Jun;10(6):2970-2987. doi: 10.21037/tlcr-20-630.
6
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.癌症多特异性抗体的原理和当前临床现状。
Int J Mol Sci. 2021 May 26;22(11):5632. doi: 10.3390/ijms22115632.
7
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.帕博利珠单抗对比化疗用于 PD-L1 肿瘤比例分数≥50%的转移性非小细胞肺癌的 5 年结果。
J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19.
8
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.免疫检查点抑制剂在肺大细胞神经内分泌肿瘤中的真实世界生存结果。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001999.
9
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies.肺癌中的免疫调节：当前概念与未来策略
Respiration. 2020 Dec 8:1-27. doi: 10.1159/000510385.
10
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives.晚期非小细胞肺癌的综合系列生物样本库：可行性、挑战与展望
Transl Lung Cancer Res. 2020 Aug;9(4):1000-1014. doi: 10.21037/tlcr-20-137.
Zotero 插件